Arcturus Therapeutics is trading at $10.39, with a -7.81% change amid biotech-sector weakness; available evidence does not establish a direct cause for the October 16 decline. - No clear company-specific announcement surfaced. The latest identified release was September 23 clinical data and a platform announcement, not a new catalyst for this move. - Biotech coverage has described investor caution amid rising rates and recent clinical setbacks; broader market pressure may also be contributing.